Genzyme Teams With French Firm to Combat Blindness

11/27/07

Cambridge, MA-based biotech giant Genzyme (NASDAQ: GENZ) has forged a research agreement with French startup Fovea Pharmaceuticals. The deal—financial terms of which were not disclosed—is aimed a developing gene-based therapies for preventing or ameliorating blindness.

By posting a comment, you agree to our terms and conditions.